Login to Your Account

Iterum's $65M series B to support pivotal trials of antibiotic sulopenem

By Nuala Moran
Staff Writer

Friday, May 19, 2017

LONDON – Iterum Therapeutics Ltd. has raised $65 million in an oversubscribed series B round to fund phase III development of sulopenem, a treatment in-licensed from Pfizer Inc. for gram-negative multidrug-resistant infections.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription